Open Clinical Trials:
CLINICAL TRIAL 20873
A Phase 1b, Open-Label Study of Relacorilant in Combination with Pembrolizumab for Patients with Adrenocortical Carcinoma with Excess Glucocorticoid Production
Disease Site: Adrenal, Adrenalcortical cancer
View Trial Details